This is a preview of subscription content, log in via an institution to check access.
Notes
tumour necrosis factor
Reference
Steenholdt C, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut : 22 Jul 2013. Available from: URL: http://dx.doi.org/10.1136/gutjnl-2013-305279
Rights and permissions
About this article
Cite this article
Individualised infliximab therapy saves costs in Crohn's disease. PharmacoEcon Outcomes News 684, 8 (2013). https://doi.org/10.1007/s40274-013-0615-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0615-z